Natixis Advisors’s Ionis Pharmaceuticals IONS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.78M | Buy |
23,721
+1,830
| +8% | +$144K | ﹤0.01% | 1155 |
|
|
2025
Q4 | $1.73M | Buy |
+21,891
| New | +$1.65M | ﹤0.01% | 1092 |
|
|
2025
Q1 | – | Sell |
-14,313
| Closed | -$500K | – | 1643 |
|
|
2024
Q4 | $500K | Sell |
14,313
-6,767
| -32% | -$253K | ﹤0.01% | 1470 |
|
|
2024
Q3 | $844K | Sell |
21,080
-2,324
| -10% | -$108K | ﹤0.01% | 1344 |
|
|
2024
Q2 | $1.11M | Buy |
23,404
+376
| +2% | +$15.4K | ﹤0.01% | 1219 |
|
|
2024
Q1 | $998K | Buy |
23,028
+5,715
| +33% | +$272K | ﹤0.01% | 1221 |
|
|
2023
Q4 | $875K | Buy |
17,313
+1,394
| +9% | +$66.8K | ﹤0.01% | 1247 |
|
|
2023
Q3 | $722K | Sell |
15,919
-279
| -2% | -$11.5K | ﹤0.01% | 1261 |
|
|
2023
Q2 | $665K | Buy |
16,198
+122
| +0.8% | +$4.69K | ﹤0.01% | 1266 |
|
|
2023
Q1 | $575K | Sell |
16,076
-127
| -0.8% | -$4.77K | ﹤0.01% | 1279 |
|
|
2022
Q4 | $612K | Buy |
16,203
+385
| +2% | +$16.2K | ﹤0.01% | 1259 |
|
|
2022
Q3 | $700K | Sell |
15,818
-12
| -0.1% | -$506 | ﹤0.01% | 1190 |
|
|
2022
Q2 | $586K | Sell |
15,830
-31
| -0.2% | -$1.17K | ﹤0.01% | 1246 |
|
|
2022
Q1 | $587K | Sell |
15,861
-34
| -0.2% | -$1.11K | ﹤0.01% | 1252 |
|
|
2021
Q4 | $484K | Sell |
15,895
-1,833
| -10% | -$57.7K | ﹤0.01% | 1247 |
|
|
2021
Q3 | $595K | Sell |
17,728
-1,136
| -6% | -$42.8K | ﹤0.01% | 1184 |
|
|
2021
Q2 | $752K | Sell |
18,864
-1,740
| -8% | -$68.2K | ﹤0.01% | 1145 |
|
|
2021
Q1 | $926K | Sell |
20,604
-4,819
| -19% | -$269K | ﹤0.01% | 1074 |
|
|
2020
Q4 | $1.44M | Sell |
25,423
-138,898
| -85% | -$6.92M | 0.01% | 921 |
|
|
2020
Q3 | $7.8M | Sell |
164,321
-3,185
| -2% | -$177K | 0.05% | 389 |
|
|
2020
Q2 | $9.88M | Buy |
167,506
+27,799
| +20% | +$1.55M | 0.07% | 315 |
|
|
2020
Q1 | $6.61M | Buy |
139,707
+825
| +0.6% | +$46K | 0.05% | 368 |
|
|
2019
Q4 | $8.39M | Buy |
138,882
+15,496
| +13% | +$923K | 0.06% | 362 |
|
|
2019
Q3 | $7.39M | Buy |
123,386
+2,182
| +2% | +$142K | 0.06% | 351 |
|
|
2019
Q2 | $7.79M | Buy |
121,204
+14,681
| +14% | +$1.04M | 0.06% | 336 |
|
|
2019
Q1 | $8.65M | Sell |
106,523
-4,065
| -4% | -$262K | 0.08% | 298 |
|
|
2018
Q4 | $5.98M | Sell |
110,588
-1,469
| -1% | -$74.9K | 0.06% | 352 |
|
|
2018
Q3 | $5.78M | Sell |
112,057
-11,794
| -10% | -$554K | 0.05% | 412 |
|
|
2018
Q2 | $5.16M | Sell |
123,851
-8,045
| -6% | -$357K | 0.05% | 444 |
|
|
2018
Q1 | $5.81M | Buy |
131,896
+4,300
| +3% | +$218K | 0.06% | 387 |
|
|
2017
Q4 | $6.42M | Buy |
127,596
+822
| +0.6% | +$45.1K | 0.07% | 345 |
|
|
2017
Q3 | $6.43M | Sell |
126,774
-3,241
| -2% | -$170K | 0.07% | 354 |
|
|
2017
Q2 | $6.61M | Buy |
130,015
+1,636
| +1% | +$76.2K | 0.07% | 340 |
|
|
2017
Q1 | $5.16M | Sell |
128,379
-4,621
| -3% | -$208K | 0.06% | 412 |
|
|
2016
Q4 | $6.36M | Buy |
133,000
+41,745
| +46% | +$1.65M | 0.08% | 326 |
|
|
2016
Q3 | $3.34M | Sell |
91,255
-6,230
| -6% | -$195K | 0.04% | 499 |
|
|
2016
Q2 | $2.27M | Buy |
97,485
+17,009
| +21% | +$549K | 0.03% | 595 |
|
|
2016
Q1 | $3.26M | Buy |
80,476
+31,206
| +63% | +$1.27M | 0.05% | 480 |
|
|
2015
Q4 | $3.05M | Buy |
49,270
+3,295
| +7% | +$178K | 0.05% | 480 |
|
|
2015
Q3 | $1.86M | Buy |
45,975
+2,095
| +5% | +$108K | 0.03% | 619 |
|
|
2015
Q2 | $2.52M | Buy |
43,880
+653
| +2% | +$41.5K | 0.04% | 554 |
|
|
2015
Q1 | $2.75M | Sell |
43,227
-1,504
| -3% | -$102K | 0.05% | 542 |
|
|
2014
Q4 | $2.76M | Buy |
44,731
+4,180
| +10% | +$206K | 0.05% | 512 |
|
|
2014
Q3 | $1.57M | Buy |
40,551
+5,444
| +16% | +$193K | 0.03% | 660 |
|
|
2014
Q2 | $1.21M | Buy |
35,107
+4,984
| +17% | +$157K | 0.02% | 770 |
|
|
2014
Q1 | $1.3M | Sell |
30,123
-2,848
| -9% | -$138K | 0.02% | 710 |
|
|
2013
Q4 | $1.31M | Sell |
32,971
-1,475
| -4% | -$52.6K | 0.02% | 673 |
|
|
2013
Q3 | $1.29M | Sell |
34,446
-8,200
| -19% | -$245K | 0.02% | 636 |
|
|
2013
Q2 | $1.15M | Buy |
+42,646
| New | +$907K | 0.02% | 647 |
|
Other funds holding IONS
VPM
VCM
Natixis Advisors's IONS Position: Q1 2026 in Review
Natixis Advisors increased its Ionis Pharmaceuticals (IONS) stake by 8.4% in Q1 2026, buying an estimated $144K and bringing the position to 23,721 shares worth $1.78M. The position accounts for ﹤0.01% of the portfolio, ranked #1155.
Natixis Advisors first reported a position in IONS in Q2 2013 and has held it in 49 quarters since. The position peaked at $9.88M in Q2 2020. 493 funds tracked by Wall St. Rank hold IONS as of Q1 2026.
- Natixis Advisors held 23,721 shares of Ionis Pharmaceuticals worth $1.78M as of Q1 2026.
- Natixis Advisors bought 1,830 Ionis Pharmaceuticals shares in Q1 2026, an estimated $144K.
- Ionis Pharmaceuticals made up ﹤0.01% of Natixis Advisors's portfolio in Q1 2026, its #1155 holding.
- Natixis Advisors first reported a position in Ionis Pharmaceuticals in Q2 2013 and has held it in 49 quarters since.
- Natixis Advisors's Ionis Pharmaceuticals position peaked at $9.88M in Q2 2020.
- 493 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2026.
Based on Natixis Advisors's 13F filing for Q1 2026, filed 13 May 2026.